X

Trial Profile

Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixazomib (Primary) ; Lenalidomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

20 Apr 2023 Status changed from active, no longer recruiting to completed.
08 Mar 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
08 Mar 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com